{
    "2019-04-15": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran",
                "features": {
                    "keywords": [
                        "Alnylam",
                        "Phase III",
                        "ENVISION",
                        "Givosiran"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Alcon Stock Is Back. The Eye-care Company Deserves a Long, Hard Look.",
                "features": {
                    "keywords": [
                        "Alcon",
                        "Stock",
                        "Eye-care",
                        "Long",
                        "Hard",
                        "Look"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}